While its US Food and Drug Administration approval and $56,000 price tag have been controversial, Biogen Inc./Eisai Co. Ltd.’s Aduhelm (aducanumab) still represents a lot of firsts as the first disease-modifying drug approved for Alzheimer’s disease and the first amyloid-targeting therapy to make it all the way across the drug development finish line. But it was far from the first attempt.
Scrip took a look through the history of the Alzheimer’s drug pipeline, drilling down into the anti-amyloid drug candidates, to...
